Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-exi...
Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )
25 Sep 2019
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk ...
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019
Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezo...
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA
Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )
25 Sep 2019
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOda...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Comparative effectiveness of lenalidomide, bortezomib, and their combinations fo...
Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
Real-world use of carfilzomib therapy among patients with existing cardiovascula...
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma pati...
Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )
25 Sep 2019
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients wi...
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2019
Iberdomide in combination with dexamethasone for multiple myeloma
Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA
Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )
25 Sep 2019